AstraZeneca Wins FDA Approval for Diabetes Drug

Feb 28, 2017

AstraZeneca has announced FDA-approval for once-daily Qtern, for the treatment of type-2 diabetes.

Qtern fixed-dose combination is intended to provide an additional oral medicine option for patients taking Farxiga, approved in 2014, to improve blood sugar level.

The combo med was delayed in 2015, after the FDA requested additional clinical data for approval.

Read the press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments